A prominent biotechnology firm is fighting back against the United States government, filing a lawsuit to overturn its placement on a restrictive military blacklist. Novogene Co., along with its California-based subsidiary, has asked a federal court in Washington D.C. to strike down a Defense Department designation that labels the organization as a company supporting the Chinese military. The move comes after the Pentagon officially blacklisted the firm in June, effectively barring it from securing various U.S. government contracts and funding.
In legal filings submitted Tuesday, Novogene argues that the Pentagon acted without sufficient evidence to justify such a severe classification. The company claims that the decision was reached through an arbitrary process that ignored factual realities about their operations. By placing them on this list, the biotech developer asserts that the government has fundamentally misunderstood its business model and relationship with foreign entities.
Beyond the dispute over facts, Novogene’s attorneys argue that the Department of Defense bypassed critical legal safeguards during the listing process. The lawsuit alleges that the agency violated the Administrative Procedure Act and trampled upon the company’s due process rights guaranteed by the Fifth Amendment. This suggests that Novogene believes it was denied a fair opportunity to contest the allegations before being branded as a security risk.
The clash highlights the growing tension between American national security interests and global scientific collaboration. As the U.S. continues to tighten oversight on firms with ties to China, more private enterprises are finding themselves caught in a geopolitical tug-of-war. For now, Novogene seeks a judicial remedy to clear its name and restore its ability to operate freely within the American market.
